Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Neurofeedback in Treatment of Attention Deficit Hyperactivity Disorder

NCT07285681 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-10-01
Last updated
2025-12-16

Condition(s) studied

Attention Deficit Disorder With Hyperactivity (ADHD)

Investigational drug(s) / intervention(s)

Neurofeedback

Neurofeedback: The aim of this study to assess the effectiveness of Neurofeedback in management of Attention Deficit Hyperactivity Disorder in a sample of patients in Tanta city, Egypt

Study summary

Attention-deficit/hyperactivity disorder (ADHD) is a common , chronic , and debilitating disorder . Although pharmacological treatments for ADHD can be easily implemented and are usually effective, their long-term therapeutic effects are still uncertain and adverse events are common, especially sleep problems, decreased appetite, and growth deceleration. Furthermore, psychosocial treatments, such eas parental training and behavioral therapy seem to be effective only during its delivery, and their effects are rarely sustained long-term .

Neurofeedback is a biofeedback method based on the rationale that there is a relationship between surface EEG and the underlying thalamocortical mechanisms responsible for its rhythms and frequency modulations .

Variations in alertness and behavioural control appear directly related to thalamocortical generator mechanisms. The principle of NF is that over time, participants learn operant control of their EEG and change from an "abnormal" state to one resembling that of typically developing children. This process is thought to eventually remediate the symptoms associated with ADHD .

Eligibility

Sex
ALL
Min age
12 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Participants are between 12- 18 years old * Both sexes are included (males \& females). * Willingness to participate to complete study procedures Exclusion Criteria: * Unwilling to participate in the study. * Other Psychiatric disorders. * Intellectual disability

Primary outcome measure(s)

  • 5. The Arabic version of Conners Rating Scale — At the baseline after 35 days after 70 days
    The Arabic version of Conners' Rating Scale was developed as a comprehensive checklist for acquiring parental reports of the basic presenting problems for children referred to an outpatient psychiatric setting .The Conners' Comprehensive Behavior Rating Scale is a questionnaire that focuses on behavioral, social, and academic issues in children and adolescents. It can help diagnose \& rate attention deficit hyperactivity disorder .The Arabic version of Conners' Rating scale is composed of 48 items divided on 6 scales. The 6 scales include: conduct disorder, learning problems, psychosomatic problems, impulsivity, hyperactivity \& anxiety It is usually considered normal when scores are less than 60, while scores above 60 are signs of academic, behavioral, or social issues. There are several different classes as well: * A T -score of more than 60 can indicate that the child may have an issue such as ADHD. * A T-score greater than 60 but under 70 may indicate moderately severe issues.
  • Collection of socio demographic data using El gilany and ElWasify scale — - Performed at base line
    Socioeconomic status(SES) is measured by 3 variables: education, occupation and income. While SES has been seen as an inherited factor, in modern society it may migrate on the basis of factors such as occupation, education, income, type of housing, material possessions. The final scale included 7 domains in the form of education , occupation, family, family possession, home sanitation, health care and economic domain with a total score of 84, with a higher score indicating better SES,

Trial sites (1)

FacilityCityRegionStatus
NeuroPsychiatry Department - Faculty of Medicine - Tanta University Tanta Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07285681 on ClinicalTrials.gov ↗ ← All trials in Egypt